Information Provided By:
Fly News Breaks for May 16, 2016
HAE
May 16, 2016 | 05:46 EDT
Goldman Sachs analyst David Roman upgraded Haemonetics to Neutral saying the risk/reward is more balanced with consensus numbers and management expectations "rebased." The analyst raised his price target for the shares to $29 from $25.
News For HAE From the Last 2 Days
There are no results for your query HAE